{"id":859207,"date":"2025-06-10T14:33:11","date_gmt":"2025-06-10T18:33:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/"},"modified":"2025-06-10T14:33:11","modified_gmt":"2025-06-10T18:33:11","slug":"urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/","title":{"rendered":"URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n NEW YORK<\/span>
\n <\/span>, June 10, 2025<\/span><\/span> \/PRNewswire\/ —<\/p>\n

\n

\n
\n \"Rosen
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Why:\u00a0Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of UroGen Pharma Ltd. (NASDAQ: URGN) between July 27, 2023<\/span> and May 15, 2025<\/span>, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than July 28, 2025<\/span>.<\/p>\n

So What: If you purchased UroGen\u00a0securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.<\/p>\n

What to do next:\u00a0To join the UroGen\u00a0class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=40032<\/a> or call Phillip Kim, Esq.<\/span> at 866-767-3653 or email case@rosenlegal.com<\/a> for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than July 28, 2025<\/span>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million<\/span> for investors. In 2020, founding partner Laurence Rosen<\/span> was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.<\/p>\n

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and\/or failed to disclose that: (1) the ENVISION clinical study was not designed to demonstrate substantial evidence of effectiveness of UGN-102 (UroGen’s lead pipeline product, which is an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer) because it lacked a concurrent control arm; (2) as a result, UroGen would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (3) UroGen failed to heed the FDA’s warnings about the study design used to support a drug application for UGN-102; (4) as a result of the foregoing, there was a substantial risk that the NDA for UGN-102 would not be approved; and (5) as a result of the foregoing, defendants’ positive statements about UroGen’s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n

To join the UroGen\u00a0class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=40032<\/a> or call Phillip Kim, Esq.<\/span> at 866-767-3653 or email case@rosenlegal.com<\/a> for more information.<\/p>\n

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.<\/p>\n

Follow us for updates on LinkedIn: https:\/\/www.linkedin.com\/company\/the-rosen-law-firm<\/a>, on Twitter: https:\/\/twitter.com\/rosen_firm<\/a> or on Facebook: https:\/\/www.facebook.com\/rosenlawfirm\/<\/a>.<\/p>\n

Attorney Advertising. Prior results do not guarantee a similar outcome.<\/p>\n

Contact Information:<\/p>\n

\n Laurence Rosen, Esq.<\/span>
\n
\n Phillip Kim, Esq.<\/span>
\n
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY<\/span> 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com<\/a>
www.rosenlegal.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit-302477883.html<\/a><\/p>\n

SOURCE THE ROSEN LAW FIRM, P. A.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK , June 10, 2025 \/PRNewswire\/ — Why:\u00a0Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of UroGen Pharma Ltd. (NASDAQ: URGN) between July 27, 2023 and May 15, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than July 28, 2025. So What: If you purchased UroGen\u00a0securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next:\u00a0To join the UroGen\u00a0class action, go to … <\/p>\n

Continue reading “URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-859207","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nURGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , June 10, 2025 \/PRNewswire\/ — Why:\u00a0Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of UroGen Pharma Ltd. (NASDAQ: URGN) between July 27, 2023 and May 15, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than July 28, 2025. So What: If you purchased UroGen\u00a0securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next:\u00a0To join the UroGen\u00a0class action, go to … Continue reading "URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T18:33:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit\",\"datePublished\":\"2025-06-10T18:33:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\\\/\"},\"wordCount\":689,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/405060\\\/Rosen_Law_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\\\/\",\"name\":\"URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/405060\\\/Rosen_Law_Logo.jpg\",\"datePublished\":\"2025-06-10T18:33:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/405060\\\/Rosen_Law_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/405060\\\/Rosen_Law_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit - Market Newsdesk","og_description":"PR Newswire NEW YORK , June 10, 2025 \/PRNewswire\/ — Why:\u00a0Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of UroGen Pharma Ltd. (NASDAQ: URGN) between July 27, 2023 and May 15, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than July 28, 2025. So What: If you purchased UroGen\u00a0securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next:\u00a0To join the UroGen\u00a0class action, go to … Continue reading \"URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-10T18:33:11+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit","datePublished":"2025-06-10T18:33:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/"},"wordCount":689,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/","name":"URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg","datePublished":"2025-06-10T18:33:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/urgn-investors-have-opportunity-to-lead-urogen-pharma-ltd-securities-fraud-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/859207","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=859207"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/859207\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=859207"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=859207"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=859207"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}